DK0696280T3 - Substituerede pyrrolidin-3-yl-alkyl-piperidiner anvendelige som tachykinin-antagonister - Google Patents

Substituerede pyrrolidin-3-yl-alkyl-piperidiner anvendelige som tachykinin-antagonister

Info

Publication number: DK0696280T3
Authority: DK; Denmark
Prior art keywords: alkyl; tachykinin antagonists; substituted pyrrolidin; piperidines; useful
Prior art date: 1993-05-06

Application number

DK94917898.2T

Other languages

English (en)

Inventor

Timothy P Burkholder

Tieu-Binh Le

Elizabeth M Kudlacz

George D Maynard

Original Assignee

Merrell Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-05-06

Filing date

1994-04-22

Publication date

1998-01-12

1994-04-22 Application filed by Merrell Pharma Inc filed Critical Merrell Pharma Inc

1998-01-12 Application granted granted Critical

1998-01-12 Publication of DK0696280T3 publication Critical patent/DK0696280T3/da

Links

102000003141 Tachykinin Human genes 0.000 title abstract 3
108060008037 tachykinin Proteins 0.000 title abstract 3
239000005557 antagonist Substances 0.000 title 1
230000008485 antagonism Effects 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 2
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 abstract 1
208000007920 Neurogenic Inflammation Diseases 0.000 abstract 1
101800000399 Neurokinin A Proteins 0.000 abstract 1
102400000097 Neurokinin A Human genes 0.000 abstract 1
HEAUFJZALFKPBA-YRVBCFNBSA-N Neurokinin A Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)C(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)O)C1=CC=CC=C1 HEAUFJZALFKPBA-YRVBCFNBSA-N 0.000 abstract 1
102100024304 Protachykinin-1 Human genes 0.000 abstract 1
101800003906 Substance P Proteins 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000000144 pharmacologic effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Immunology (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)

DK94917898.2T 1993-05-06 1994-04-22 Substituerede pyrrolidin-3-yl-alkyl-piperidiner anvendelige som tachykinin-antagonister DK0696280T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US5860693A	1993-05-06	1993-05-06
US21848394A	1994-03-28	1994-03-28
US22537194A	1994-04-19	1994-04-19

Publications (1)

Publication Number	Publication Date
DK0696280T3 true DK0696280T3 (da)	1998-01-12

Family

ID=27369482

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK94917898.2T DK0696280T3 (da)	1993-05-06	1994-04-22	Substituerede pyrrolidin-3-yl-alkyl-piperidiner anvendelige som tachykinin-antagonister

Country Status (18)

Country	Link
EP (1)	EP0696280B1 (da)
JP (1)	JP3424174B2 (da)
CN (1)	CN1081635C (da)
AT (1)	ATE158580T1 (da)
AU (1)	AU678023B2 (da)
CA (1)	CA2160462C (da)
DE (1)	DE69405862T2 (da)
DK (1)	DK0696280T3 (da)
ES (1)	ES2110761T3 (da)
FI (1)	FI113047B (da)
GR (1)	GR3025475T3 (da)
HU (1)	HU224496B1 (da)
IL (1)	IL109496A (da)
MX (1)	MX9403386A (da)
NO (1)	NO309144B1 (da)
NZ (1)	NZ267209A (da)
TW (1)	TW281675B (da)
WO (1)	WO1994026735A1 (da)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2717802B1 (fr) *	1994-03-25	1996-06-21	Sanofi Sa	Nouveaux composés aromatiques, procédé pour leur préparation et compositions pharmaceutiques en contenant.
MX9701305A (es)	1994-08-25	1998-05-31	Merrell Pharma Inc	Piperidinas sustituidas novedosas utiles para el tratamiento de enfermedades alergicas.
EP0714891A1 (en) *	1994-11-22	1996-06-05	Eli Lilly And Company	Heterocyclic tachykinin receptor antagonists
FR2728169A1 (fr) *	1994-12-19	1996-06-21	Oreal	Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728165A1 (fr) *	1994-12-19	1996-06-21	Oreal	Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
FR2729954B1 (fr) *	1995-01-30	1997-08-01	Sanofi Sa	Composes heterocycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
AU697599B2 (en) *	1995-03-15	1998-10-08	Aventis Pharmaceuticals Inc.	Heterocyclic substituted piperazinone derivatives as tachykinin receptor antagonists
CN1098255C (zh) *	1995-04-13	2003-01-08	阿温蒂斯药物公司	新的具有速激肽受体拮抗活性的取代的哌嗪衍生物
US5661163A (en) *	1995-06-07	1997-08-26	Merck & Co., Inc.	Alpha-1a adrenergic receptor antagonists
FR2738245B1 (fr) *	1995-08-28	1997-11-21	Sanofi Sa	Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
FR2738819B1 (fr) *	1995-09-14	1997-12-05	Sanofi Sa	Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant
EP0854720B1 (en)	1995-10-10	1999-08-04	Pfizer Inc.	Nk-1 receptor antagonists for prevention of neurogenic inflammation in gene therapy
US6211199B1 (en)	1995-11-17	2001-04-03	Aventis Pharmaceuticals Inc.	Substituted 4-(1H-benzimidazol-2-yl-amino)piperidines useful for the treatment of allergic diseases
HU224225B1 (hu)	1995-12-01	2005-06-28	Sankyo Co. Ltd.	Tachikinin receptor antagonista hatású heterociklusos vegyületek, ezek előállítási eljárása és alkalmazásuk gyógyszerkészítmények előállítására
US6194406B1 (en)	1995-12-20	2001-02-27	Aventis Pharmaceuticals Inc.	Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic disease
KR20000064487A (ko) *	1995-12-20	2000-11-06	게리 디. 스트리트, 스티븐 엘. 네스비트	알레르기질환의치료에유용한신규의치환된4-(1h-벤즈이미다졸-2-일)1,4디아제판
US6423704B2 (en)	1995-12-20	2002-07-23	Aventis Pharmaceuticals Inc.	Substituted 4-(1H-benzimidazol-2-yl)[1,4]diazepanes useful for the treatment of allergic diseases
GB9600235D0 (en)	1996-01-05	1996-03-06	Pfizer Ltd	Therapeutic agents
US5922737A (en) *	1996-02-21	1999-07-13	Hoechst Marion Roussel, Inc.	Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
US5998439A (en) *	1996-02-21	1999-12-07	Hoescht Marion Roussel, Inc.	Substituted N-methyl-N-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
US5932571A (en) *	1996-02-21	1999-08-03	Hoechst Marion Roussel, Inc.	Substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) {1,4}diazepan-1-yl)-2-(aryl) butyl) benzamides useful for the treatment of allergic diseases
US5977139A (en) *	1996-12-15	1999-11-02	Hoechst Marion Roussel, Inc.	Carboxysubstituted cyclic carboxamide derivatives
AU718984B2 (en) *	1996-12-19	2000-05-04	Aventis Pharmaceuticals Inc.	Novel carboxy substituted cyclic carboxamide derivatives
US5861417A (en) *	1996-12-19	1999-01-19	Hoechst Marion Roussel, Inc.	Heterocyclic substituted pyrrolidine amide derivatives
IL130223A (en) *	1996-12-19	2005-09-25	Aventis Pharma Inc	Heterocyclic substituted pyrrolidine amide derivatives, process for their preparation and pharmaceutical compositions containing them
BR9809713A (pt)	1997-05-30	2000-07-11	Sankyo Co	Composto, medicamento e composição compreendendo o mesmo, uso do composto, e, processos para profilaxia ou tratamento de doenças mediadas com taquicinina, para inibir um receptor nk1 e/ou um receptor nk2, e para profilaxia ou tratamento de asma e/ou bronquite, de rinite, de alergia, e, de incontinência urinária
ID29137A (id) *	1998-07-27	2001-08-02	Schering Corp	Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US7163949B1 (en)	1999-11-03	2007-01-16	Amr Technology, Inc.	4-phenyl substituted tetrahydroisoquinolines and use thereof
MXPA02004330A (es)	1999-11-03	2004-07-30	Albany Molecular Res Inc	Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina..
KR100821410B1 (ko)	2000-07-11	2008-04-10	에이엠알 테크놀로지, 인크.	4-페닐 치환된 테트라하이드로이소퀴놀린 및 이의치료학적 용도
AU2003296992A1 (en) *	2002-12-13	2004-07-09	Smithkline Beecham Corporation	Pyrrolidine and azetidine compounds as ccr5 antagonists
TW200524868A (en)	2003-07-31	2005-08-01	Zeria Pharm Co Ltd	Benzylamine derivatives
EP1679069A4 (en) *	2003-10-21	2009-05-13	Dainippon Sumitomo Pharma Co	NEW PIPERIDINE DERIVATIVE
GB0412865D0 (en) *	2004-06-09	2004-07-14	Glaxo Group Ltd	Chemical compounds
UA91341C2 (ru)	2004-07-15	2010-07-26	Амр Текнолоджи, Інк.	Арил- и гетероарилзамещенные тетрагидроизохинолины и их применение для блокирования обратного захвата норэпинефрина, допамина и серотонина
AU2005299852B2 (en) *	2004-10-22	2011-08-04	Merck Sharp & Dohme Corp.	CGRP receptor antagonists
AU2006227199A1 (en)	2005-03-22	2006-09-28	Azevan Pharmaceuticals, Inc.	Beta-lactamylalkanoic acids for treating premenstrual disorders
WO2006123182A2 (en)	2005-05-17	2006-11-23	Merck Sharp & Dohme Limited	Cyclohexyl sulphones for treatment of cancer
UA95454C2 (uk)	2005-07-15	2011-08-10	Амр Текнолоджи, Інк.	Арил- і гетероарилзаміщені тетрагідробензазепіни і їх застосування для блокування зворотного захоплення норепінефрину, допаміну і серотоніну
KR101523776B1 (ko)	2005-07-19	2015-05-28	아제반 파마슈티칼스, 인코퍼레이티드	베타-락타민 페닐알라닌, 시스테인 그리고 세린 바소프레신길항물질
BRPI0616463A2 (pt)	2005-09-29	2011-06-21	Merck & Co Inc	composto, composição farmacêutica, e, uso de um composto
GB0603041D0 (en)	2006-02-15	2006-03-29	Angeletti P Ist Richerche Bio	Therapeutic compounds
JP5489333B2 (ja)	2006-09-22	2014-05-14	メルク・シャープ・アンド・ドーム・コーポレーション	脂肪酸合成阻害剤を用いた治療の方法
US20110218176A1 (en)	2006-11-01	2011-09-08	Barbara Brooke Jennings-Spring	Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CN101190330A (zh)	2006-11-30	2008-06-04	深圳市鼎兴生物医药技术开发有限公司	胆碱酯酶在拮抗速激肽药物中的应用
AR064777A1 (es)	2007-01-10	2009-04-22	Inst Di Reserche D Biolog Mole	Indazoles sustituidos con amida como inhibidores de poli (adp- ribosa) polimerasa (parp)
WO2008090114A1 (en)	2007-01-24	2008-07-31	Glaxo Group Limited	Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
CA2682727C (en)	2007-04-02	2016-03-22	Banyu Pharmaceutical Co., Ltd.	Indoledione derivative
EP3103791B1 (en)	2007-06-27	2018-01-31	Merck Sharp & Dohme Corp.	4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CN102014631A (zh)	2008-03-03	2011-04-13	泰格尔医药科技公司	酪氨酸激酶抑制剂
US9156812B2 (en)	2008-06-04	2015-10-13	Bristol-Myers Squibb Company	Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en)	2009-04-01	2010-10-07	Merck Sharp & Dohme Corp.	Inhibitors of akt activity
AU2010247763B2 (en)	2009-05-12	2015-12-24	Albany Molecular Research, Inc.	7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
US8815894B2 (en)	2009-05-12	2014-08-26	Bristol-Myers Squibb Company	Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof
EP2429295B1 (en)	2009-05-12	2013-12-25	Albany Molecular Research, Inc.	Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
US8859776B2 (en)	2009-10-14	2014-10-14	Merck Sharp & Dohme Corp.	Substituted piperidines that increase p53 activity and the uses thereof
US8921394B2 (en)	2010-04-27	2014-12-30	Merck Sharp & Dohme Corp.	Prolylcarboxypeptidase inhibitors
US8999957B2 (en)	2010-06-24	2015-04-07	Merck Sharp & Dohme Corp.	Heterocyclic compounds as ERK inhibitors
WO2012003436A1 (en)	2010-07-01	2012-01-05	Azevan Pharmaceuticals, Inc.	Methods for treating post traumatic stress disorder
CA2805265A1 (en)	2010-08-02	2012-02-09	Merck Sharp & Dohme Corp.	Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
WO2012024170A2 (en)	2010-08-17	2012-02-23	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8883801B2 (en)	2010-08-23	2014-11-11	Merck Sharp & Dohme Corp.	Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (en)	2010-09-01	2012-03-08	Schering Corporation	Indazole derivatives useful as erk inhibitors
US9242981B2 (en)	2010-09-16	2016-01-26	Merck Sharp & Dohme Corp.	Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en)	2010-10-29	2012-05-03	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
EP2654748B1 (en)	2010-12-21	2016-07-27	Merck Sharp & Dohme Corp.	Indazole derivatives useful as erk inhibitors
WO2012143879A1 (en)	2011-04-21	2012-10-26	Piramal Healthcare Limited	A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (en)	2011-10-27	2018-04-04	Merck Sharp & Dohme Corp.	Novel compounds that are erk inhibitors
WO2013165816A2 (en)	2012-05-02	2013-11-07	Merck Sharp & Dohme Corp.	SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
WO2014052563A2 (en)	2012-09-28	2014-04-03	Merck Sharp & Dohme Corp.	Novel compounds that are erk inhibitors
ME02925B (me)	2012-11-28	2018-04-20	Merck Sharp & Dohme	Kompozicije i postupci za liječenje kancera
TW201429969A (zh)	2012-12-20	2014-08-01	Merck Sharp & Dohme	作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
WO2014120748A1 (en)	2013-01-30	2014-08-07	Merck Sharp & Dohme Corp.	2,6,7,8 substituted purines as hdm2 inhibitors
US20160194368A1 (en)	2013-09-03	2016-07-07	Moderna Therapeutics, Inc.	Circular polynucleotides
NZ724718A (en)	2014-03-28	2023-04-28	Azevan Pharmaceuticals Inc	Compositions and methods for treating neurodegenerative diseases
EP3317279B1 (en) *	2015-07-03	2021-01-27	H. Hoffnabb-La Roche Ag	Triaza-spirodecanones as ddr1 inhibitors
US10975084B2 (en)	2016-10-12	2021-04-13	Merck Sharp & Dohme Corp.	KDM5 inhibitors
WO2019055913A1 (en)	2017-09-15	2019-03-21	Azevan Pharmaceuticals, Inc.	COMPOSITIONS AND METHODS FOR TREATMENT OF BRAIN INJURY
EP3706747B1 (en)	2017-11-08	2025-09-03	Merck Sharp & Dohme LLC	Prmt5 inhibitors
US10947234B2 (en)	2017-11-08	2021-03-16	Merck Sharp & Dohme Corp.	PRMT5 inhibitors
WO2020033282A1 (en)	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Prmt5 inhibitors
US11981701B2 (en)	2018-08-07	2024-05-14	Merck Sharp & Dohme Llc	PRMT5 inhibitors
WO2020033288A1 (en)	2018-08-07	2020-02-13	Merck Sharp & Dohme Corp.	Prmt5 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL99320A (en) *	1990-09-05	1995-07-31	Sanofi Sa	Arylalkylamines, their preparation and pharmaceutical compositions containing them
FR2676055B1 (fr) *	1991-05-03	1993-09-03	Sanofi Elf	Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.

1994
- 1994-04-22 AT AT94917898T patent/ATE158580T1/de not_active IP Right Cessation
- 1994-04-22 HU HU9503153A patent/HU224496B1/hu not_active IP Right Cessation
- 1994-04-22 AU AU69426/94A patent/AU678023B2/en not_active Ceased
- 1994-04-22 ES ES94917898T patent/ES2110761T3/es not_active Expired - Lifetime
- 1994-04-22 CA CA002160462A patent/CA2160462C/en not_active Expired - Fee Related
- 1994-04-22 DE DE69405862T patent/DE69405862T2/de not_active Expired - Lifetime
- 1994-04-22 CN CN94192362A patent/CN1081635C/zh not_active Expired - Fee Related
- 1994-04-22 JP JP52545394A patent/JP3424174B2/ja not_active Expired - Fee Related
- 1994-04-22 DK DK94917898.2T patent/DK0696280T3/da active
- 1994-04-22 EP EP94917898A patent/EP0696280B1/en not_active Expired - Lifetime
- 1994-04-22 NZ NZ267209A patent/NZ267209A/en unknown
- 1994-04-22 WO PCT/US1994/004498 patent/WO1994026735A1/en not_active Ceased
- 1994-04-26 TW TW083103768A patent/TW281675B/zh active
- 1994-05-02 IL IL10949694A patent/IL109496A/xx not_active IP Right Cessation
- 1994-05-06 MX MX9403386A patent/MX9403386A/es unknown
1995
- 1995-11-02 FI FI955258A patent/FI113047B/fi not_active IP Right Cessation
- 1995-11-03 NO NO954400A patent/NO309144B1/no not_active IP Right Cessation
1997
- 1997-11-26 GR GR970403124T patent/GR3025475T3/el unknown

Also Published As

Publication number	Publication date
IL109496A0 (en)	1994-08-26
AU6942694A (en)	1994-12-12
IL109496A (en)	2000-07-26
HU224496B1 (hu)	2005-10-28
ATE158580T1 (de)	1997-10-15
EP0696280B1 (en)	1997-09-24
JP3424174B2 (ja)	2003-07-07
CN1081635C (zh)	2002-03-27
MX9403386A (es)	1995-01-31
WO1994026735A1 (en)	1994-11-24
NZ267209A (en)	1997-09-22
TW281675B (da)	1996-07-21
DE69405862T2 (de)	1998-01-15
CN1124961A (zh)	1996-06-19
GR3025475T3 (en)	1998-02-27
AU678023B2 (en)	1997-05-15
HUT74085A (en)	1996-11-28
ES2110761T3 (es)	1998-02-16
EP0696280A1 (en)	1996-02-14
FI955258A0 (fi)	1995-11-02
DE69405862D1 (de)	1997-10-30
NO309144B1 (no)	2000-12-18
HU9503153D0 (en)	1996-01-29
FI113047B (fi)	2004-02-27
CA2160462C (en)	1998-12-15
NO954400L (no)	1996-01-08
CA2160462A1 (en)	1994-11-24
FI955258L (fi)	1995-11-30
NO954400D0 (no)	1995-11-03
JPH09500361A (ja)	1997-01-14

Publication	Publication Date	Title
DK0696280T3 (da)	1998-01-12	Substituerede pyrrolidin-3-yl-alkyl-piperidiner anvendelige som tachykinin-antagonister
BR9917080A (pt)	2002-03-12	Composto, composição farmacêutica, uso do composto e método de tratamento ou prevenção de uma disfunção tromboembólica
SE9504661D0 (sv)	1995-12-22	New compounds
DK0889877T3 (da)	2001-10-01	Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
PT894084E (pt)	2002-11-29	Derivados de acido cinamico e sua utilizacao como antagonistas de integrina
ES2160949T3 (es)	2001-11-16	Derivados de fenilen-sulfonamida sustituidos en meta.
RU95101048A (ru)	1996-10-27	Производные пролинамида, фармкомпозиция на их основе
DE69713152D1 (de)	2002-07-11	Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
DK0726893T3 (da)	2000-05-29	Hidtil ukendte 4-piperidinyl-substituerede lactamer som neurokinon 2-receptor-antagonister til behandling af astma
NO950757L (no)	1995-04-27	Antitussiv
WO1999026932A8 (en)	1999-09-10	By amidino group substituted heterocyclic derivatives and their use as anticoagulants
YU30902A (sh)	2005-07-19	Novi ciklopropani kao cgrp antagonisti, lekovi koji sadrže navedena jedinjenja i postupak za njihovu proizvodnju
DK0733051T3 (da)	2000-04-03	Bicykliske, heterocykliske forbindelser som neurokinin A-antagonister
CO4560412A1 (es)	1998-02-10	Piperidonas
UA41350C2 (uk)	2001-09-17	Похідна морфоліну або її фармацевтично прийнятна сіль та фармацевтична композиція на її основі
SE9504662D0 (sv)	1995-12-22	New compounds
RU95109891A (ru)	1997-02-10	19,11-перекрытые мостиками 4-эстрены, способ их получения, содержащая их фармацевтическая композиция и промежуточные соединения для их получения
RU94036762A (ru)	1996-09-10	Гетероарилпиперидины, способ их получения, промежуточные соединения синтеза и фармацевтическая композиция
UA37217C2 (uk)	2001-05-15	Аналоги 15-дезоксиспергуаліну, спосіб їх одержання, фармацевтична композиція та проміжні сполуки
ES2065855B1 (es)	1995-09-01	Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.
UY26971A1 (es)	2002-06-20	Nuevos antagonistas de neuroquinina, procedimiento para su preparación y composiciones farmacéuticas que contienen estos compuestos
RU93044977A (ru)	1996-06-20	Ароматические производные аминов и способ их получения
SE9304065D0 (sv)	1993-12-06	New compound
RU94010096A (ru)	1995-11-10	Производное 1,2,5,6-тетрагидропиридина, способ его получения и фармацевтическая композиция
ITMI922969A0 (it)	1992-12-24	Nuovi peptidi sintetici, processo per la loro preparazione, composizioni farmaceutiche che li contengono e loro impiego per la somministrazione di farmaci attraverso la barriera emato-encefalica e la retina.